Tag: PHA MTC HEA BIO

Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025

Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, Aug. 7, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a...

INOVIO Announces Pricing of $25 Million Public Offering

PLYMOUTH MEETING, Pa., July 3, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to...

Dizal’s ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20insApproval follows the U.S. FDA's Priority Review and is supported by the pivotal WU-KONG1 Part B study, in which...

Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA’s 85th Scientific Sessions

SAN FRANCISCO and SUZHOU, China, June 12, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and...

Everest Medicines Presents Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of Novel BTK Inhibitor EVER001 at the 62nd Congress of the...

EVER001 is a covalent reversible BTK inhibitor with potentially best-in-class characteristics for the treatment of primary membranous nephropathy (pMN) and other autoimmune renal diseases, including...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsPHA MTC HEA BIO

In HelloNation, Auto Industry Experts David Mantz and David Mantz Jr. Examine Choosing the Right Mechanic in Southington, Connecticut

POST HOUSE REPORTS 88% YEAR-OVER-YEAR REVENUE GROWTH AS DEMAND FOR LUXURY WELLNESS EXPERIENCES ACCELERATES IN THE HAMPTONS

Canadian Investment Regulatory Organization Trading Halt – TVK

Tag: PHA MTC HEA BIO

Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025

INOVIO Announces Pricing of $25 Million Public Offering

Dizal’s ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA’s 85th Scientific Sessions

Everest Medicines Presents Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of Novel BTK Inhibitor EVER001 at the 62nd Congress of the...

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us